3
By Pragyan Kalita Sept 25 (Reuters) – Shares of ADARx Pharmaceuticals rose 30% above their initial public offering price on Friday after the late-stage gene therapy developer raised $446.3 million in
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
